MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals
RETA
|
+$5.34M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$4.37M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$3.12M |
| 4 |
Relmada Therapeutics
RLMD
|
+$2.85M |
| 5 |
TPTX
Turning Point Therapeutics
TPTX
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lite Strategy
LITS
|
+$33M |
| 2 |
iTeos Therapeutics
ITOS
|
+$3.59M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$367K |
| 4 |
Cytokinetics
CYTK
|
+$285K |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$265K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q1 2022 Portfolio in Review
As of Q1 2022, MPM BioImpact held 38 positions worth $373M, down 32% from $549M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
MPM BioImpact withdrew a net $17M in Q1 2022, closing 1 position and reducing 17 holdings. Its most notable exit was Lite Strategy, an estimated $33M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM BioImpact opened a new position in Reata Pharmaceuticals worth $5.9M.
- MPM BioImpact's largest Q1 2022 buy was Reata Pharmaceuticals: 180,000 shares worth $5.9M.
- MPM BioImpact added most to Turning Point Therapeutics in Q1 2022, an estimated $2.69M increase.
- MPM BioImpact's biggest Q1 2022 reduction was iTeos Therapeutics, cutting an estimated $3.59M.
- MPM BioImpact fully exited Lite Strategy in Q1 2022, selling an estimated $33M.
- MPM BioImpact's ten largest holdings make up 67% of its $373M portfolio in Q1 2022.
- MPM BioImpact opened 5 new positions and closed 1 in Q1 2022.
- MPM BioImpact's portfolio value fell 32% quarter-over-quarter to $373M.
Based on MPM BioImpact's 13F filing for Q1 2022, filed 13 May 2022.